Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0000950170-25-113692

Chief R&D Officer sold 1,721 shares at an average $33.52 ($57,693)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2025-09-04 Sale : show line 1 in the form 10b5-1 −793 $32.43 $25,717 18,390 D
2025-09-04 Sale : show line 2 in the form 10b5-1 −432 $33.60 $14,515 17,958 D
2025-09-04 Sale : show line 3 in the form 10b5-1 −189 $34.41 $6,503 17,769 D
2025-09-04 Sale : show line 4 in the form 10b5-1 −307 $35.69 $10,957 17,462 D
Open-market sales · 1,721 sh · avg $33.52 · $57,693
Loading xslF345X05/ownership.xml…